Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

FORDE S. MATTHEWS J.D. JAHANGIRI L. LEE L. PROKOPH N. MALCOLM T.I. GIGER O. BELL N. BLAIR H. O'MARCAIGH A. SMITH O. KENNER L. BOMKEN S. BURKE G.A.A. TURNER Suzanne Dawn

Year of publication 2021
Type Article in Periodical
Magazine / Source BRITISH JOURNAL OF HAEMATOLOGY
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://onlinelibrary.wiley.com/doi/10.1111/bjh.17043
Doi http://dx.doi.org/10.1111/bjh.17043
Keywords Burkitt lymphomapatient derived xenograftrelapseB-cell lymphomamurine cancer models
Description Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by aMYCtranslocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.

You are running an old browser version. We recommend updating your browser to its latest version.

More info